title: The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer.
abstract: OBJECTIVE
  To evaluate the association of tumor-derived matrix metalloproteinase 2 (MMP-2) and stromal-derived MMP-2 expression with the prognosis of patients with ovarian cancer, a meta-analysis study was performed, which was aimed to comprehensively review the evidence of MMP-2 as prognostic biomarkers in ovarian cancers.
  
  
  METHODS
  All relevant studies were searched in PubMed and Web of Science until May 30, 2014. Hazard ratios (HRs) with their 95% confidence intervals (CIs) were used to assess the association between MMP-2 expression (tumor-derived or stromal-derived) and prognosis of patients with ovarian cancer. Pooled odds ratios (ORs) and their 95% CIs were used to assess the correlation of MMP-2 expression with the clinicopathological features of patients with ovarian cancer.
  
  
  RESULTS
  A total of 965 patients in 8 studies were included in this analysis. Among them, tumor-derived and stromal-derived MMP-2 expression was detected in 7 and 5 articles, respectively. The results revealed that ovarian cancer patients with positive tumor-derived MMP-2 expression showed a worse prognosis than did the ones with negative tumor-derived MMP-2 expression (HR, 1.52; 95% CI, 1.06-2.20). However, ovarian cancer patients with positive stromal-derived MMP-2 expression had not. In addition, we also found that tumor-derived MMP-2 expression was associated with distant metastasis (absent vs present; pooled OR, 4.52; 95% CI, 1.56-13.09; P = 0.001).
  
  
  CONCLUSIONS
  These results suggested that positive tumor-derived MMP-2 expression could predict a lower overall survival rate and could be an independent dangerous prognostic factor in patients with ovarian cancer.
authors.affiliation: *Nanjing Maternal and Child Health Institute; †Department of Clinical Laboratory, Nanjing Maternal and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China.
authors.forename: Ziyi
authors.initials: Z
authors.lastname: Fu
authors.forename: Sujuan
authors.initials: S
authors.lastname: Xu
authors.forename: Ye
authors.initials: Y
authors.lastname: Xu
authors.forename: Jiehua
authors.initials: J
authors.lastname: Ma
authors.forename: Jingyun
authors.initials: J
authors.lastname: Li
authors.forename: Pengfei
authors.initials: P
authors.lastname: Xu
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D018450:Disease Progression; D005260:Female; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000032:analysis*; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000473:pathology; D011379:Prognosis; D017154:Stromal Cells / Q000201:enzymology*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D020778:Matrix Metalloproteinase 2